Fuji Photo Film Company, Limited

Fujifilm Corporation

Masaru Takasaki

Katsuyuki Watanabe

Toshiki Fujiwara

Tomohiro Chino

Hisashi Okamura

Minoru Sakai

Hiroyuki Suzuki

Tadashi Inaba

Toshihide Ezoe

Yoshiharu Yabuki

Shigeo Hirano

Keiichi Tateishi

Nobuo Seto

Nobuaki Inoue

Kohzaburoh Yamada

Yoshihiko Fujie

Takahiro Goto

Shigeaki Tanaka

Toyohisa Oya

Kouta Fukui

Mamoru Sakurazawa

Yoshimitsu Arai

Tadanobu Sato

Masahiko Taniguchi

Shinichi Ichikawa

Atsushi Matsunaga

Hideki Maeta

Daisuke Terada

Atsushi Hirai

Shinya Hayashi

Tomoki Naoe

Hitoshi Kiyoi

Takahiro Matsuno

Shinsuke Mizumoto

Kimihiko Sato

Shinji Hagiwara

Megumi Ookubo

Shinsuke Inuki

Atsush Hirai

Yasuhiro Kawanishi

Daisuke Hirano

Toshiyuki Nakatani

Takeshi Yamaura

Toshiaki Tsujino

Shintarou Tanabe

Tadao Sekioka

Takahiro Morita

Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation. 

Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof

The object is to provide an Fms-like tyrosine kinase 3 (FLT3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (AML). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided. The compound or a salt thereof of the present invention can be used as an active ingredient of a pharmaceutical composition for a treatment of a disease or condition relating to FLT3, such as acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).

Nitrogen-containing heterocyclic compound or salt thereof

Provided is an azo pigment represented by the following general formula (1), a tautomer of the azo pigment, and a salt or a hydrate thereof: wherein Q represents the non-metallic atoms necessary to complete a 5- to 7-membered heterocyclic group, W represents an alkoxy group, an amino group, an alkyl group, or an aryl group, Xand Xeach independently represents a hydrogen, an alkyl group, an acyl group, an alkylsulfonyl group, or an arylsulfonyl group, Rrepresents a hydrogen or a substituent, Rrepresents a heterocyclic group, n represents an integer of from 1 to 4 and the general formula (1) represents a dimer formed through Q, W, X, X, R, or Rwhen n=2, a trimer formed through Q, W, X, X, R, or Rwhen n=3, and a tetramer formed through Q, W, X, X, R, or Rwhen n=4.

Azo pigments, and pigment dispersion, coloring composition and ink for inkjet recording containing the azo pigment

An ink set includes at least a magenta ink composition and a cyan ink composition, wherein the magenta ink composition includes: at least one colorant selected from the group consisting of specific heterylazo dyes; and at least one colorant selected from the group consisting of specific anthrapyridone dyes, and the cyan ink composition includes at least one colorant selected from the group consisting of phthalocyanine compounds meeting requirements 1 and 2: Requirement 1: The ratio of the maximum absorbance within the absorption band of from 660 nm to 680 nm to the maximum absorbance within the absorption band of from 600 nm to 640 nm on the spectral absorption curve of aqueous solution is less than 1; and Requirement 2: The oxidation potential is more positive than 1.0 eV (vsSCE).

Ink set and inkjet recording method

An azo dye represented by formula (II) as defined in the specification, a process of producing the same and a coloring composition containing the azo dye. 

Azo dye, ink jet recording ink, heat sensitive recording material, color toner, color filter, ink jet recording method, ink cartridge and ink jet printer

An ink composition which comprises: a dye which is represented by formula (1), which is described in the specification, and has at least one ionic hydrophilic group, wherein the dye has a molecular weight of from 310 to 500 per one ionic hydrophilic group, and a recording method which comprises: discharging ink droplets of the ink composition onto plain paper.

Ink composition and recording method

An ink containing an azo dye having, in total, at least 13 conjugated &#x3c0; electrons in an aromatic ring thereof that is not directly bonded to any azo group.

Ink and ink-jet recording ink

The invention provides a water-soluble ink capable of forming an image having good color hue and high fastness in various use and environmental conditions, which comprises a coloring composition comprising a disazo dye represented by the following formula 1: A-N&#x2550;N-A-N&#x2550;N-Aand at least one other dye having a specific structure; in formula 1, A, Aand Aeach independently represents an aromatic group which may be substituted or a heterocyclic group which may be substituted, and Aand Aeach is a monovalent group and Ais a divalent group.

Coloring composition and inkjet recording method

An aqueous ink comprising at least two dyes each having at least one ionic hydrophilic group in a molecule thereof, wherein at least one of said at least two dyes includes an azo dye represented by formula (1):  wherein A and B each independently represents a substituted or unsubstituted monovalent aromatic group; or a substituted or unsubstituted monovalent heterocyclic group; Rrepresents a hydrogen atom; a substituted or unsubstituted aromatic group; or a substituted or unsubstituted heterocyclic group; and X represents &#x2014;CR&#x2550; or a nitrogen atom, and when X represents &#x2014;CR&#x2550;, Rrepresents a hydrogen atom or a substituent.

Aqueous ink

An aqueous ink comprising at least one dye having at least one ionic hydrophilic group within a molecule thereof and represented by the following formula (1): wherein A and B each independently represents a substituted or unsubstituted monovalent aromatic group or a substituted or unsubstituted monovalent heterocyclic group, Rrepresents a substituted or unsubstituted aromatic group excluding an unsubstituted phenyl group or a substituted or unsubstituted heterocyclic group, and Rrepresents a substituent.

Aqueous ink and inkjet recording ink

A light-sensitive silver halide grain containing at least one metal complex, wherein when an a-axis, a b-axis and a c-axis of a silver halide crystal lattice are each established taking as an origin a central metal of the metal complex incorporated into the silver halide grain, the metal complex has in a ligand thereof a site which can form any bond of a covalent bond, a dative bond and an ionic bond, or a bond in a mixed form of these bonds with a silver ion on a lattice point which does not exist on any of the a-axis, the b-axis and the c-axis. The silver halide photographic material has no reciprocity failure over a wide range of exposure illuminations without desensitization and decrease of contrast on the low intensity side.

Growing community of inventors

Kanagawa, Japan

Masaru Takasaki